Li Ming

Dr. Li Ming


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MFMingyue Fan
Mingyue Fan
SYShiyao Yin
Shiyao Yin
ZZZhijie Zhou
Zhijie Zhou
LMLi Ming
Li Ming
YLYanan Li
Yanan Li
Background/Objectives: Enhancing lipid peroxide formation while impairing antioxidant defenses represents a promising strategy for ferroptosis-based cancer therapy. This study aimed to evaluate a tumor-derived extracellular vesicle (EV) formulation combining ALOX15-associated lipid oxidation with RSL3-mediated inhibition of GPX4. Methods: RSL3@ALOX15-MPs were prepared by associating the GPX4 inhibitor RSL3 with ALOX15-containing EVs derived from 4T1 tumor cells. The formulation was characterized, and its effects on lipid oxidation, cell viability, and ferroptosis-associated responses were evaluated in vitro. Antitumor efficacy, biodistribution, tumor immune-cell phenotypes, and preliminary tolerability were assessed in 4T1 tumor-bearing mice. Results: The formulation exhibited EV-associated characteristics and an RSL3 loading content of approximately 3.8% relative to MP protein mass. In 4T1 cells, RSL3@ALOX15-MPs increased BODIPY-C11 oxidation to approximately five times the PBS control level and reduced cell viability to approximately 30%, compared with approximately 60% following RSL3-MP treatment. Ferrostatin-1, liproxstatin-1, and deferoxamine partially rescued cell viability and attenuated lipid oxidation. RSL3-containing formulations reduced total glutathione peroxidase activity, while ALOX15 inhibition attenuated lipid oxidation and cytotoxicity. The combined formulation also resulted in lower cell viability than a physical mixture of the individual formulations. In vivo, RSL3@ALOX15-MPs increased tumor RSL3 accumulation, altered intratumoral immune-cell phenotypes and cytokine levels, inhibited tumor growth, and prolonged survival. Conclusions: Combining ALOX15-associated lipid oxidation with RSL3 delivery using tumor-derived EVs enhanced ferroptosis-associated cytotoxicity in vitro and demonstrated antitumor efficacy in the 4T1 tumor model. Further studies are required to establish GPX4-specific effects and the causal contributions of ferroptosis and immune responses to the in vivo therapeutic outcomes.